Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 3/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22536768 | 0.94 | NCEH1 (0.34) | HTR5ANCEH1ACHEBCHEKDM4E | |
| SCHEMBL22536766 | 0.89 | NCEH1 (0.33) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL29879820 | 0.88 | ACHE (0.32) | HTR5ANCEH1ACHEBCHE | |
| SCHEMBL22536767 | 0.87 | NCEH1 (0.31) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL20816208 | 0.86 | PDE4A (0.36) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL22536765 | 0.84 | NCEH1 (0.36) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL20816198 | 0.84 | SLC2A1 (0.33) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL18123588 | 0.83 | LTA4H (0.34) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL29880006 | 0.83 | LTA4H (0.34) | NCEH1KDM4EMAPTRECQLKMT2A | |
| Sulfuric Acid SCHEMBL29880001 | 0.83 | LTA4H (0.33) | NCEH1KDM4EMAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | claimed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | HTR5A 1576/4885NCEH1 966/4885ACHE 2839/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | HTR5A 1576/4885NCEH1 966/4885ACHE 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.